<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266368</url>
  </required_header>
  <id_info>
    <org_study_id>Antimicrobeal ureteral stents</org_study_id>
    <nct_id>NCT02266368</nct_id>
  </id_info>
  <brief_title>Comparison of Antimicrobial Coated Ureteral Stents With Non-coated Stents</brief_title>
  <official_title>A Randomized Controlled Trial Comparing Antimicrobial Coated (Silver Sulfadiazine) Ureteral Stents With Non-coated Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to compare the efficacy of antimicrobial coated ureteral stent
      with non-coated stents in prevention of UTI in patients with ureteral stents
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy of antimicrobial coated of ureteral stent with silver sulphadiazine in
      prevention of UTI in patients with ureteral stents will be studied by comparining the results
      of urine and stent cultures with patients who had non-coated ureteral stents. The impact of
      antimicrobeal stent coating on patients' quality of life will be evaluated with comparing the
      scores of ureteral stent symptom questionnaire between both groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of urinary tract infection (UTI)</measure>
    <time_frame>up to 3 months</time_frame>
    <description>UTI will be diagnosed with urine and stent culture of stent removal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 3 months</time_frame>
    <description>The impact of stent coating on quality of life will be assissed with ureteral stent symptom questionnaire (USSQ)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will include patients with non-coated stents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antimicrobeal group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will include patients with antimicrobeal coated stents</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Antimicrobeal coated stents</intervention_name>
    <description>Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents</description>
    <arm_group_label>Antimicrobeal group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who will undergo ureteral stent placement

        Exclusion Criteria:

          -  Patients allergic to sulpha containing medications

          -  Ureteral stent insertion for infected hydronephrosis

          -  Patients who developed septic complications requiring antibiotic treatment after stent
             placement

          -  Patients who need bilateral stents

          -  Patients with chronic kidney disease grade IV and V (GFR &lt;30ml/min)

          -  Immunocompromised patients as those with malignancy or organ transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed R EL-NAHAS, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant Professour, urology department, urology and nephrology center, mansoura university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology and Nephrology Center</name>
      <address>
        <city>Mansoura</city>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2014</study_first_submitted>
  <study_first_submitted_qc>October 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed R. EL-Nahas</investigator_full_name>
    <investigator_title>Assisstant Professor</investigator_title>
  </responsible_party>
  <keyword>Ureteral stents</keyword>
  <keyword>Double J stent</keyword>
  <keyword>Antimicoreal coated stent</keyword>
  <keyword>USSQ</keyword>
  <keyword>UTI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

